Evidence map›Paper›PMID 40671014›Full record

ArticleBMC chemistry2025

Total synthesis and biological evaluation of Koshidacin B, TAN-1746, and Ac-TAN-1746.

Xiong-En Long, Hailiang Xing, Yixin He, Xuanli Meng, Yanling Ma, Chang Liu, Xi Cao, Huiru Nan, Min-Jing Cheng, Jia-Lei Yan and 1 more

Abstract read
In one paragraph

Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiong-En Long *School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China.
Hailiang Xing *School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China.
Yixin He *Center for Bioactive Natural Molecules and Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Xuanli MengCenter for Bioactive Natural Molecules and Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Yanling MaSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China.
Chang LiuCenter for Bioactive Natural Molecules and Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
Xi CaoSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China.
Huiru NanSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China.
Min-Jing ChengCenter for Bioactive Natural Molecules and Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China. chengmj1235@jnu.edu.cn.
Jia-Lei YanSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. yanjialei@wyu.edu.cn.
Junyang LiuSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. liujy@wyu.edu.cn.

Funding

Department of Education of Guangdong Province 2021ZDJS097Guangdong Basic and Applied Basic Research Foundation 2022A1515110592, 2023A1515012715, and 2025A1515011064Jiangmen Basic and Applied Basic Research Project 202301003003140National Natural Science Foundation of China 82473801, 82104019Science & Technology Projects in Guangzhou 2025A04J3399
6 · The paper itself

Abstract

Analogues of chlamydocin derivatives consistently demonstrate multifaceted bioactivities, particularly through HDAC inhibition mechanisms, oncolytic efficacy, and neuronal preservation capacities. These activities primarily originate from their unique cyclic tetrapeptide scaffold and functional groups within the side chains that enable specific interactions with biomacromolecules. We herein report the total syntheses of three naturally occurring chlamydocin analogues-koshidacin B, TAN-1746, and Ac-TAN-1746. The synthetic strategy employed a modular approach that involved modifying a common intermediate via late-stage olefin cross-metathesis to install the requisite side-chain fragments. This versatile approach enabled an efficient and divergent total synthesis of the target compounds, completing the syntheses in a longest linear sequence of 9-10 steps. Remarkably, TAN-1746 and Ac-TAN-1746 demonstrated significant anti-osteosarcoma activity that exceeded the potency of clinically employed cisplatin-an observation not previously documented. These results strongly validate the utility of the chlamydocin scaffold as a platform for the development of potent inhibitors with promising therapeutic potential.

Indexed as

Chlamydocin analogCross metathesisKoshidacin BTAN-1746Total synthesis

Identifiers

PMID40671014
PMCPMC12265328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.